SCHEMBL16474641

SCHEMBL16474641

Cc1cc(=O)n(-c2ccc(OC(F)(F)F)cc2)cc1-c1cnc2nccn2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.40
GAA P10253 2/20 0.40
MAPT P10636 2/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40
MCHR1 Q99705 3/20 0.40
DYRK1A Q13627 1/20 0.37
GRM5 P41594 3/20 0.36
POLB P06746 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 1/20 0.35
PPARG P37231 2/20 0.35
PPARD Q03181 2/20 0.35
PPARA Q07869 2/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
NAMPT P43490 1/20 0.34
CYP1A2 P05177 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18077715 0.87 GRM5 (0.40) DYRK1AGRM5CYP1A2
SCHEMBL16474644 0.85 GRM2 (0.42) KDM4EGAAMAPTMCHR1MAPK1
SCHEMBL20190138 0.82 SCN5A (0.47) KDM4EGAAMAPTNPC1ALDH1A1
SCHEMBL16474633 0.81 PPARD (0.40) KDM4EGAAMAPTMCHR1POLB
SCHEMBL16475244 0.81 MAPT (0.43) KDM4EGAAMAPTMCHR1POLB
SCHEMBL16474635 0.80 POLB (0.41) KDM4EGAAMAPTMCHR1POLB
SCHEMBL10059859 0.79 ABL1 (0.48) KDM4EGAAMAPTMCHR1POLB
SCHEMBL16474632 0.79 ABL1 (0.52) NPC1RAB9ADYRK1APTGS2ABL1
SCHEMBL16474554 0.78 MCHR1 (0.41) KDM4EGAAMAPTNPC1RAB9A
SCHEMBL16474622 0.77 ABL1 (0.43) KDM4EGAAMAPTMCHR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 KDM4E 2117/4885GAA 1734/4885MAPT 4377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.